

1 S. 154 - An analysis on cost impact of legislation to improve health insurance coverage for biomarker testing

Will you support S 154, as passed by the Senate, an interim study to improve health insurance coverage for biomarker testing?

- Biomarker testing helps connect patients with the right treatment at the right time.
- Biomarker testing opens the door to personalized medicine, including targeted therapy, which can help to achieve better health outcomes, improved quality of life and reduced costs.
- 60% of oncology drugs launched in the past five years require or recommend biomarker testing prior to use.
- 55% of cancer clinical trials in 2018 involved biomarker testing.
- Biomarker research is expanding beyond oncology to benefit patients with heart disease, neurological conditions (e.g., Alzheimer's), infectious diseases, and respiratory illnesses.
- Access to biomarker testing can help lower long-term healthcare costs by connecting patients with more effective treatments and avoiding unnecessary or ineffective therapies.